Magnus Gisslén
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magnus Gisslén has a total of 418 co-authors. Here are the top co-authors by number of shared publications:
- Henrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
14 shared publications - Dietmar Fuchs
Institute of Biological Chemistry, Medizinische Universität Innsbruck, Innsbruck, Austria
12 shared publications - Staffan Nilsson
Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg
10 shared publications Dietmar Fuchs
Institute of Medical Biological Chemistry, Innsbruck Medical University
9 shared publications- Fredrik Nyberg
School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
9 shared publications Lars Hagberg
Department of Infectious Diseases, Sahlgrenska Academy, Institute of Biomedicine, University of Gothenburg, Sweden; Department of Infectious Diseases, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
9 shared publications
Latest Publications
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (10) , 2670-2685
Predictors of Critical Illness During Different COVID-19 Pandemic Periods Compared With Seasonal Influenza
OBJECTIVES: Since the onset of the COVID-19-pandemic, emerging virus variants, increasing population immunity, and evolving treatment strategies have substantially altered disease severity. This study aimed to identify predictors of critical illness due to COVID-19 over time and compare them with those of seasonal influenza in Sweden. DESIGN, SETTING, PATIENTS, AND MEASUREMENTS: We conducted a retrospective, population-based cohort study using nationwide registry data. All individuals hospitalized for COVID-19 between 2020 and 2022 were categorized into five groups, based on pandemic waves and dominating virus variants. A sixth group included all patients hospitalized for influenza between 2018 and 2022. Patients were followed from hospitalization until ICU admission, in-hospital death, discharge, or end of study. Incidence rates were calculated and Cox regression identified predictors of ICU admission and in-hospital mortality, adjusting for age, sex, socioeconomic factors, comorbidities, and severe acute respiratory syndrome corona virus 2-vaccination. Data on influenza vaccinations were not available from the registers. MAIN RESULTS: We included 92,428 COVID-19 hospitalizations and 21,355 influenza hospitalizations. Hospitalization rates were lowest during the delta-dominant period, while ICU admission rates were lowest during the Omicron-dominant period. The Omicron period most closely resembled influenza inpatient demographics, hospital stay duration, ICU admissions, and in-hospital mortality. Age distributions varied across pandemic periods, with the Omicron period showing an age profile similar to influenza (≈ 50% ≥ 75 yr). Adjusted hazard ratios for ICU-admission were strongest in unvaccinated patients, males, and individuals of 45–74 years for COVID-19, and in individuals of 45–64 years or with chronic lung diseases for influenza. Common predictors of in-hospital mortality included age older than 45 years (with a sharp increase after 74), male sex, and chronic comorbidities, and for COVID-19 also unvaccinated status. CONCLUSIONS: Although COVID-19 consistently resulted in higher hospitalization rates than influenza, demographic and clinical patterns converged during the later pandemic stages. Advanced age was the strongest predictor of severe illness in both infections, with lack of vaccination additionally associated with severe COVID-19.
- 7 September 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 54 (10) , 2670-2685
Predictors of Critical Illness During Different COVID-19 Pandemic Periods Compared With Seasonal Influenza
OBJECTIVES: Since the onset of the COVID-19-pandemic, emerging virus variants, increasing population immunity, and evolving treatment strategies have substantially altered disease severity. This study aimed to identify predictors of critical illness due to COVID-19 over time and compare them with those of seasonal influenza in Sweden. DESIGN, SETTING, PATIENTS, AND MEASUREMENTS: We conducted a retrospective, population-based cohort study using nationwide registry data. All individuals hospitalized for COVID-19 between 2020 and 2022 were categorized into five groups, based on pandemic waves and dominating virus variants. A sixth group included all patients hospitalized for influenza between 2018 and 2022. Patients were followed from hospitalization until ICU admission, in-hospital death, discharge, or end of study. Incidence rates were calculated and Cox regression identified predictors of ICU admission and in-hospital mortality, adjusting for age, sex, socioeconomic factors, comorbidities, and severe acute respiratory syndrome corona virus 2-vaccination. Data on influenza vaccinations were not available from the registers. MAIN RESULTS: We included 92,428 COVID-19 hospitalizations and 21,355 influenza hospitalizations. Hospitalization rates were lowest during the delta-dominant period, while ICU admission rates were lowest during the Omicron-dominant period. The Omicron period most closely resembled influenza inpatient demographics, hospital stay duration, ICU admissions, and in-hospital mortality. Age distributions varied across pandemic periods, with the Omicron period showing an age profile similar to influenza (≈ 50% ≥ 75 yr). Adjusted hazard ratios for ICU-admission were strongest in unvaccinated patients, males, and individuals of 45–74 years for COVID-19, and in individuals of 45–64 years or with chronic lung diseases for influenza. Common predictors of in-hospital mortality included age older than 45 years (with a sharp increase after 74), male sex, and chronic comorbidities, and for COVID-19 also unvaccinated status. CONCLUSIONS: Although COVID-19 consistently resulted in higher hospitalization rates than influenza, demographic and clinical patterns converged during the later pandemic stages. Advanced age was the strongest predictor of severe illness in both infections, with lack of vaccination additionally associated with severe COVID-19.
- Open Access
- 26 July 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171, 109007
Modeled assumptions should not be mistaken for measured prevention
- 26 July 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 171, 109007
Open AccessModeled assumptions should not be mistaken for measured prevention
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1252-e1261
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
Background: Type 2 diabetes mellitus (T2DM) is common among people with HIV (PWH), although studies comparing T2DM-related complications in people with and without HIV (PWoH) remain limited. This was assessed using data from the Cohort Study on Morbidity and HIV in Sweden (COSMOHS). Methods: Nationwide study including Swedish residents born 1930–2006, diagnosed with T2DM between 2010 and 2019, followed until 31 December 2024, using 7 national registers including national HIV and diabetes registers. Follow-up began at T2DM diagnosis. Outcomes included renal events, cardiovascular events, and all-cause mortality. Cox proportional regression estimated hazard ratios (adjHRs) by HIV status, stratified by propensity score quintiles of age, sex, migrant status, comorbidities, and socioeconomics. Results: 350 PWH and 311 668 PWoH were included, with similar median follow-up time (PWH, 7.8 years; PWoH, 8.8 years). PWH had higher renal risk than PWoH (major adverse kidney event: adjHR, 2.04; 95% CI, 1.57-2.65) but no significantly increased cardiovascular risk (major adverse cardiovascular event: adjHR, 1.18; 95% CI, .87–1.60) or all-cause mortality. Findings were consistent across sensitivity analyses, including competing-risk models for death and excluding PWH receiving tenofovir disoproxil fumarate at baseline. Accounting for the benign plasma/serum-creatinine increase associated with bictegravir, cobicistat, dolutegravir, and rilpivirine, the increased renal risk remained, although not statistically significant. The renal risk was most prominent in PWH with BMI ≥30 kg/m2. Conclusions: In this nationwide cohort, PWH with T2DM exhibited higher risk of renal complications than PWoH, indicating enhanced renal monitoring may be warranted. Further research should investigate underlying mechanisms, including antiretroviral therapy, to guide clinical management.
- 18 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , e1252-e1261
Open AccessRenal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
Background: Type 2 diabetes mellitus (T2DM) is common among people with HIV (PWH), although studies comparing T2DM-related complications in people with and without HIV (PWoH) remain limited. This was assessed using data from the Cohort Study on Morbidity and HIV in Sweden (COSMOHS). Methods: Nationwide study including Swedish residents born 1930–2006, diagnosed with T2DM between 2010 and 2019, followed until 31 December 2024, using 7 national registers including national HIV and diabetes registers. Follow-up began at T2DM diagnosis. Outcomes included renal events, cardiovascular events, and all-cause mortality. Cox proportional regression estimated hazard ratios (adjHRs) by HIV status, stratified by propensity score quintiles of age, sex, migrant status, comorbidities, and socioeconomics. Results: 350 PWH and 311 668 PWoH were included, with similar median follow-up time (PWH, 7.8 years; PWoH, 8.8 years). PWH had higher renal risk than PWoH (major adverse kidney event: adjHR, 2.04; 95% CI, 1.57-2.65) but no significantly increased cardiovascular risk (major adverse cardiovascular event: adjHR, 1.18; 95% CI, .87–1.60) or all-cause mortality. Findings were consistent across sensitivity analyses, including competing-risk models for death and excluding PWH receiving tenofovir disoproxil fumarate at baseline. Accounting for the benign plasma/serum-creatinine increase associated with bictegravir, cobicistat, dolutegravir, and rilpivirine, the increased renal risk remained, although not statistically significant. The renal risk was most prominent in PWH with BMI ≥30 kg/m2. Conclusions: In this nationwide cohort, PWH with T2DM exhibited higher risk of renal complications than PWoH, indicating enhanced renal monitoring may be warranted. Further research should investigate underlying mechanisms, including antiretroviral therapy, to guide clinical management.
- Open Access
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1072-1078
Effect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial
Phosphodiesterase-5 (PDE-5) inhibitors may be beneficial in Alzheimer's disease (AD). We assessed the PDE-5 inhibitor tadalafil effect on plasma biomarkers of neurodegeneration in 15 individuals with type 2 diabetes post-hoc in a randomized placebo-controlled trial (ClinicalTrials.gov: NCT02601989) at Sahlgrenska University Hospital. Tadalafil reduced plasma amyloid-β 40 and 42 but not the 42/40 ratio over a 6-week treatment period. Glial fibrillary acidic protein was reduced, but not phosphorylated tau217, neurofilament light protein or growth/differentiation factor 15. Tadalafil reduced plasma levels of biomarkers for amyloid metabolism and astroglial activation in patients with diabetes. Designated clinical trials are warranted to validate these results.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1072-1078
Open AccessEffect of 6-week tadalafil treatment on blood-based biomarkers of neurodegeneration: A post-hoc analysis of a randomized controlled trial
Phosphodiesterase-5 (PDE-5) inhibitors may be beneficial in Alzheimer's disease (AD). We assessed the PDE-5 inhibitor tadalafil effect on plasma biomarkers of neurodegeneration in 15 individuals with type 2 diabetes post-hoc in a randomized placebo-controlled trial (ClinicalTrials.gov: NCT02601989) at Sahlgrenska University Hospital. Tadalafil reduced plasma amyloid-β 40 and 42 but not the 42/40 ratio over a 6-week treatment period. Glial fibrillary acidic protein was reduced, but not phosphorylated tau217, neurofilament light protein or growth/differentiation factor 15. Tadalafil reduced plasma levels of biomarkers for amyloid metabolism and astroglial activation in patients with diabetes. Designated clinical trials are warranted to validate these results.
- Open Access
- 19 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e913-e922
Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy
Background: This study evaluates the degree of neuroaxonal injury during acute HIV infection (AHI) in neuroasymptomatic individuals and the neuroprotective effect of antiretroviral therapy (ART) initiated during AHI, by measuring neurofilament light (NFL), glial fibrillary acidic protein (GFAP) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) samples collected during pre-ART AHI and at post-ART visits up to 5 years. Methods: RV254 cohort participants (99% male, median age 27 years) were enrolled during Fiebig I-V AHI. A subset completed optional lumbar punctures during pre-ART AHI (week 0, n = 136) and/or at post-ART visits with HIV suppression (weeks 24, 48, 96; and 240, n = 201). RV254 CSF NFL measurements were compared to those of 44 people without HIV (PWoH), both adjusted to a sampling age of 30, and to age-based upper normal limits (UNL). Results: RV254 participants demonstrated higher CSF NFL than PWoH at pre-ART AHI (P < .001), and post-ART weeks 24 (P < .001) and 48 or later (week 48+, P = .003). CSF NFL was elevated (ie, >UNL) in 15%, 8%, and 7% of RV254 participants at weeks 0, 24, and 48 + respectively, versus 2% among PWoH. During AHI, elevated CSF NFL was associated with later Fiebig stages (III-V) (P = .034), higher CSF HIV RNA (P = .012) and a smaller difference between HIV RNA in the plasma and CSF (P = .002). Additionally, CSF NFL increased with GFAP and sTREM2 during pre-ART AHI and post-ART visits (P < .050). Conclusions: CNS injury may occur during AHI. Additionally, early ART alone is likely insufficient to provide complete neuroprotection.
- 19 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e913-e922
Open AccessNeuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy
Background: This study evaluates the degree of neuroaxonal injury during acute HIV infection (AHI) in neuroasymptomatic individuals and the neuroprotective effect of antiretroviral therapy (ART) initiated during AHI, by measuring neurofilament light (NFL), glial fibrillary acidic protein (GFAP) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) samples collected during pre-ART AHI and at post-ART visits up to 5 years. Methods: RV254 cohort participants (99% male, median age 27 years) were enrolled during Fiebig I-V AHI. A subset completed optional lumbar punctures during pre-ART AHI (week 0, n = 136) and/or at post-ART visits with HIV suppression (weeks 24, 48, 96; and 240, n = 201). RV254 CSF NFL measurements were compared to those of 44 people without HIV (PWoH), both adjusted to a sampling age of 30, and to age-based upper normal limits (UNL). Results: RV254 participants demonstrated higher CSF NFL than PWoH at pre-ART AHI (P < .001), and post-ART weeks 24 (P < .001) and 48 or later (week 48+, P = .003). CSF NFL was elevated (ie, >UNL) in 15%, 8%, and 7% of RV254 participants at weeks 0, 24, and 48 + respectively, versus 2% among PWoH. During AHI, elevated CSF NFL was associated with later Fiebig stages (III-V) (P = .034), higher CSF HIV RNA (P = .012) and a smaller difference between HIV RNA in the plasma and CSF (P = .002). Additionally, CSF NFL increased with GFAP and sTREM2 during pre-ART AHI and post-ART visits (P < .050). Conclusions: CNS injury may occur during AHI. Additionally, early ART alone is likely insufficient to provide complete neuroprotection.
- Open Access
- 4 April 2025
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 35 (4) , 752-759
Sexually transmitted infections among pre-exposure prophylaxis users in a Swedish multi-centre cohort
An additional upsurge in bacterial STIs has been observed in Sweden following HIV pre-exposure prophylaxis (PrEP) implementation. From a prevention perspective, it is of relevance to optimize testing strategies within PrEP programmes to identify those most at risk. An open retrospective longitudinal observational cohort study was performed at three STI clinics in Uppsala, Gothenburg, and Malmö. A questionnaire and journal data regarding STI were collected from a sample of 199 MSM enrolled in the PrEP programmes and providing informed consent. Incident bacterial STIs during follow-up were analyzed with descriptive statistics, Poisson regression, and Cox regression. Median follow-up time was 632 days. A total of 270 gonorrhoea or chlamydia infections were recorded during PrEP follow-up, compared to 194 cases in the 2-year period prior to enrolment, giving an incidence rate ratio (IRR) of 1.56 (CI 95% 1.30–1.89). The testing frequency increased by 75% (IRR 1.69, CI 95% 1.60–1.90). For diagnoses of active syphilis, the increase was 108% (IRR 2.08. CI 95% 1.04–4.06), compared with a 5-year period preceding enrolment. The hazard ratio of time (days) until a first STI after PrEP initiation was 2.87 (CI 95% 1.72–4.80) for those having had a STI prior to PrEP initiation and 2.06 (CI 95% 1.03–4.13) for those reporting experience of group sex in the past year compared with those who had not. STI prior to PrEP initiation and group sex were associated with STI after initiation of PrEP, factors that could be considered if needing prioritizing the frequency of STI screening.
- 4 April 2025
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 35 (4) , 752-759
Open AccessSexually transmitted infections among pre-exposure prophylaxis users in a Swedish multi-centre cohort
An additional upsurge in bacterial STIs has been observed in Sweden following HIV pre-exposure prophylaxis (PrEP) implementation. From a prevention perspective, it is of relevance to optimize testing strategies within PrEP programmes to identify those most at risk. An open retrospective longitudinal observational cohort study was performed at three STI clinics in Uppsala, Gothenburg, and Malmö. A questionnaire and journal data regarding STI were collected from a sample of 199 MSM enrolled in the PrEP programmes and providing informed consent. Incident bacterial STIs during follow-up were analyzed with descriptive statistics, Poisson regression, and Cox regression. Median follow-up time was 632 days. A total of 270 gonorrhoea or chlamydia infections were recorded during PrEP follow-up, compared to 194 cases in the 2-year period prior to enrolment, giving an incidence rate ratio (IRR) of 1.56 (CI 95% 1.30–1.89). The testing frequency increased by 75% (IRR 1.69, CI 95% 1.60–1.90). For diagnoses of active syphilis, the increase was 108% (IRR 2.08. CI 95% 1.04–4.06), compared with a 5-year period preceding enrolment. The hazard ratio of time (days) until a first STI after PrEP initiation was 2.87 (CI 95% 1.72–4.80) for those having had a STI prior to PrEP initiation and 2.06 (CI 95% 1.03–4.13) for those reporting experience of group sex in the past year compared with those who had not. STI prior to PrEP initiation and group sex were associated with STI after initiation of PrEP, factors that could be considered if needing prioritizing the frequency of STI screening.
- Open Access
Multi-molecular phenotyping in a self-sampling population
The recent COVID-19 pandemic has posed major health challenges. To expand our molecular understanding beyond those seeking medical care, we conducted a cross-sectional survey targeting random residents from Sweden’s two largest cities. Two thousand participants were invited during 2021 to self-sample dried blood spots (DBS) and provide health information. DBS samples were analysed for multiple anti-SARS-CoV-2 antibodies (Abs), auto-reactive antibodies (AAbs) against 23 interferons (IFNs), and for 502 circulating immune-related proteins. Data-driven methodologies characterised the DBS phenotypes in response to infections and vaccination. We received DBS samples from 437 (22%) volunteers aged 18-69, 60% females, and 50% per city. Multi-analyte serology distinguished self-reported infections (26%) and vaccination (40%), revealing a time-dependent discrepancy between reported and measured immunity. Anti-IFN Abs were detected in 21% of the donors and more frequent for type 1 IFNs alongside a natural infection. Integrating proteomics with antibody data provided additional insights into processes of cell-mediated immunity. Proteomics-centric analysis identified 24% of the participants to deviate in their phenotypes due to infection, immunity, respiratory distress, and age-related traits. Multi-molecular analysis of layperson samples uncovered heterogeneity and diversity of immunity and health phenotypes, complementing clinical investigations.
Open AccessMulti-molecular phenotyping in a self-sampling population
The recent COVID-19 pandemic has posed major health challenges. To expand our molecular understanding beyond those seeking medical care, we conducted a cross-sectional survey targeting random residents from Sweden’s two largest cities. Two thousand participants were invited during 2021 to self-sample dried blood spots (DBS) and provide health information. DBS samples were analysed for multiple anti-SARS-CoV-2 antibodies (Abs), auto-reactive antibodies (AAbs) against 23 interferons (IFNs), and for 502 circulating immune-related proteins. Data-driven methodologies characterised the DBS phenotypes in response to infections and vaccination. We received DBS samples from 437 (22%) volunteers aged 18-69, 60% females, and 50% per city. Multi-analyte serology distinguished self-reported infections (26%) and vaccination (40%), revealing a time-dependent discrepancy between reported and measured immunity. Anti-IFN Abs were detected in 21% of the donors and more frequent for type 1 IFNs alongside a natural infection. Integrating proteomics with antibody data provided additional insights into processes of cell-mediated immunity. Proteomics-centric analysis identified 24% of the participants to deviate in their phenotypes due to infection, immunity, respiratory distress, and age-related traits. Multi-molecular analysis of layperson samples uncovered heterogeneity and diversity of immunity and health phenotypes, complementing clinical investigations.
- Open Access
- 30 October 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e57514
Person-Centered Web-Based Mobile Health System (Symptoms) for Reporting Symptoms in COVID-19 Vaccinated Individuals: Observational Study of System, Users, and Symptoms
Background: The full spectrum of side effects from COVID-19 vaccinations and infections, including milder symptoms or health effects that do not lead to health care visits, remains unknown. Person-centered self-reporting of symptoms may offer a solution. Monitoring patient-reported outcomes over time will vary in importance for different patients. Individuals have unique needs and preferences, in terms of both communication methods and how the collected information is used to support care. Objective: This study aims to describe how Symptoms, a system for person-centered self-reporting of symptoms and health-related quality of life, was utilized in investigating COVID-19 vaccine side effects. We illustrate this by presenting data from the Symptoms system in newly vaccinated individuals from the RECOVAC (Register-based large-scale national population study to monitor COVID-19 vaccination effectiveness and safety) study. Methods: During the COVID-19 pandemic, newly vaccinated individuals were identified as the ideal population to query for milder symptoms related to COVID-19 vaccinations and infections. To this end, we used posters in observation areas at 150 vaccination sites across the Västra Götaland region of Sweden, inviting newly vaccinated individuals to use a novel digital system, Symptoms. In the Symptoms system, users can track their symptoms, functioning, and quality of life as often as they wish, using evidence-based patient-reported outcome measures and short numeric rating scales. These scales cover a prespecified list of symptoms based on common COVID-19 symptoms and previously reported vaccine side effects. Participants could also use numeric rating scales for self-defined symptoms if their symptom was not included on the prespecified list. Results: A total of 731 people created user accounts and consented to share data for research between July 21, 2021, and September 27, 2022. The majority of users were female (444/731, 60.7%), with a median age of 38 (IQR 30-47) years. Most participants (498/702, 70.9%) did not report any of the comorbidities included in the questionnaire. Of the 731 participants, 563 (77.0%) reported experiencing 1 or more symptoms. The most common symptom was pain at the injection site (486/563, 86.3%), followed by fatigue (181/563, 32.1%) and headache (169/563, 30.0%). In total, 143 unique symptoms were reported. Of these, 29 were from the prespecified list, while the remaining 114 (79.7%) were self-defined entries in the symptom field. This suggests that the flexibility of the self-directed system—allowing individuals to decide which symptoms they consider worth tracking—may be an important feature. Conclusions: Self-reported symptoms in the Symptoms system appeared to align with previously observed post–COVID-19 vaccination symptoms. The system was relatively easy to use and successfully captured broad, longitudinal data. Its person-centered and self-directed design seemed crucial in capturing the full burden of symptoms experienced by users.
- 30 October 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e57514
Open AccessPerson-Centered Web-Based Mobile Health System (Symptoms) for Reporting Symptoms in COVID-19 Vaccinated Individuals: Observational Study of System, Users, and Symptoms
Background: The full spectrum of side effects from COVID-19 vaccinations and infections, including milder symptoms or health effects that do not lead to health care visits, remains unknown. Person-centered self-reporting of symptoms may offer a solution. Monitoring patient-reported outcomes over time will vary in importance for different patients. Individuals have unique needs and preferences, in terms of both communication methods and how the collected information is used to support care. Objective: This study aims to describe how Symptoms, a system for person-centered self-reporting of symptoms and health-related quality of life, was utilized in investigating COVID-19 vaccine side effects. We illustrate this by presenting data from the Symptoms system in newly vaccinated individuals from the RECOVAC (Register-based large-scale national population study to monitor COVID-19 vaccination effectiveness and safety) study. Methods: During the COVID-19 pandemic, newly vaccinated individuals were identified as the ideal population to query for milder symptoms related to COVID-19 vaccinations and infections. To this end, we used posters in observation areas at 150 vaccination sites across the Västra Götaland region of Sweden, inviting newly vaccinated individuals to use a novel digital system, Symptoms. In the Symptoms system, users can track their symptoms, functioning, and quality of life as often as they wish, using evidence-based patient-reported outcome measures and short numeric rating scales. These scales cover a prespecified list of symptoms based on common COVID-19 symptoms and previously reported vaccine side effects. Participants could also use numeric rating scales for self-defined symptoms if their symptom was not included on the prespecified list. Results: A total of 731 people created user accounts and consented to share data for research between July 21, 2021, and September 27, 2022. The majority of users were female (444/731, 60.7%), with a median age of 38 (IQR 30-47) years. Most participants (498/702, 70.9%) did not report any of the comorbidities included in the questionnaire. Of the 731 participants, 563 (77.0%) reported experiencing 1 or more symptoms. The most common symptom was pain at the injection site (486/563, 86.3%), followed by fatigue (181/563, 32.1%) and headache (169/563, 30.0%). In total, 143 unique symptoms were reported. Of these, 29 were from the prespecified list, while the remaining 114 (79.7%) were self-defined entries in the symptom field. This suggests that the flexibility of the self-directed system—allowing individuals to decide which symptoms they consider worth tracking—may be an important feature. Conclusions: Self-reported symptoms in the Symptoms system appeared to align with previously observed post–COVID-19 vaccination symptoms. The system was relatively easy to use and successfully captured broad, longitudinal data. Its person-centered and self-directed design seemed crucial in capturing the full burden of symptoms experienced by users.
- Open Access
- 10 October 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (41) , 2400021
Early unrecognised SARS-CoV-2 introductions shaped the first pandemic wave, Sweden, 2020
Background: Despite the unprecedented measures implemented globally in early 2020 to prevent the spread of SARS-CoV-2, Sweden, as many other countries, experienced a severe first wave during the COVID-19 pandemic. Aim: We investigated the introduction and spread of SARS-CoV-2 into Sweden. Methods: We analysed stored respiratory specimens (n = 1,979), sampled 7 February–2 April 2020, by PCR for SARS-CoV-2 and sequenced PCR-positive specimens. Sequences generated from newly detected cases and stored positive specimens February–June 2020 (n = 954) were combined with sequences (Sweden: n = 730; other countries: n = 129,913) retrieved from other sources for Nextstrain clade assignment and phylogenetic analyses. Results: Twelve previously unrecognised SARS-CoV-2 cases were identified: the earliest was sampled on 3 March, 1 week before recognised community transmission. We showed an early influx of clades 20A and 20B from Italy (201/328, 61% of cases exposed abroad) and clades 19A and 20C from Austria (61/328, 19%). Clade 20C dominated the first wave (20C: 908/1,684, 54%; 20B: 438/1,684, 26%; 20A: 263/1,684, 16%), and 800 of 1,684 (48%) Swedish sequences formed a country-specific 20C cluster defined by a spike mutation (G24368T). At the regional level, the proportion of clade 20C sequences correlated with an earlier weighted mean date of COVID-19 deaths. Conclusion: Community transmission in Sweden started when mitigation efforts still focused on preventing influx. This created a transmission advantage for clade 20C, likely introduced from ongoing cryptic spread in Austria. Therefore, pandemic preparedness should have a comprehensive approach, including capacity for large-scale diagnostics to allow early detection of travel-related cases and community transmission.
- 10 October 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (41) , 2400021
Open AccessEarly unrecognised SARS-CoV-2 introductions shaped the first pandemic wave, Sweden, 2020
Background: Despite the unprecedented measures implemented globally in early 2020 to prevent the spread of SARS-CoV-2, Sweden, as many other countries, experienced a severe first wave during the COVID-19 pandemic. Aim: We investigated the introduction and spread of SARS-CoV-2 into Sweden. Methods: We analysed stored respiratory specimens (n = 1,979), sampled 7 February–2 April 2020, by PCR for SARS-CoV-2 and sequenced PCR-positive specimens. Sequences generated from newly detected cases and stored positive specimens February–June 2020 (n = 954) were combined with sequences (Sweden: n = 730; other countries: n = 129,913) retrieved from other sources for Nextstrain clade assignment and phylogenetic analyses. Results: Twelve previously unrecognised SARS-CoV-2 cases were identified: the earliest was sampled on 3 March, 1 week before recognised community transmission. We showed an early influx of clades 20A and 20B from Italy (201/328, 61% of cases exposed abroad) and clades 19A and 20C from Austria (61/328, 19%). Clade 20C dominated the first wave (20C: 908/1,684, 54%; 20B: 438/1,684, 26%; 20A: 263/1,684, 16%), and 800 of 1,684 (48%) Swedish sequences formed a country-specific 20C cluster defined by a spike mutation (G24368T). At the regional level, the proportion of clade 20C sequences correlated with an earlier weighted mean date of COVID-19 deaths. Conclusion: Community transmission in Sweden started when mitigation efforts still focused on preventing influx. This created a transmission advantage for clade 20C, likely introduced from ongoing cryptic spread in Austria. Therefore, pandemic preparedness should have a comprehensive approach, including capacity for large-scale diagnostics to allow early detection of travel-related cases and community transmission.